Skip to content
Screener

Net Change in Cash at other companies

Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$120.57M+492%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$11.36M-1,124%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$49.04M-27.9%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
-$641K-103%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$49.73M+379%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
-$6.28M-353%

Other financials

Income statement

See full
Revenue$53.0K-97.3%
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Cash & equivalents$206.4M+173%
Total debt$584.0K
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%
CapEx--100%
Free cash flow-$2.7M+72.0%

Valuation

See full
Market cap$2.23B+417%
Enterprise value$2.03B

Profitability

See full
Operating margin-183.2%
Net margin71.7%+40.4pp
FCF margin-99.8%-34.2pp

Returns & leverage

See full
Return on equity-34.2%
Debt / equity
Current ratio28.9×+20.0×

Where this comes from

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 8:30 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-210463
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Payment of financing cost in connection with equity financing(14,247)
Payment of contingent value right liability(1,978)
Proceeds from exercise of stock options95667
Net cash provided by (used in) financing activities214,731(1,202)
Effect of exchange rate change on cash and cash equivalents(15)(6)
Net increase (decrease) in cash and cash equivalents148,412(7,976)
Cash and cash equivalents at beginning of period57,98283,602
Cash and cash equivalents at end of period$206,394$75,626

Item 1. Financial Statements.

FAQ

What is Palvella Therapeutics's net change in cash?
Palvella Therapeutics (PVLA) reported net change in cash of $148.41M in Q1 2026.
How has Palvella Therapeutics's net change in cash changed year-over-year?
Palvella Therapeutics's net change in cash increased by 1960.7% year-over-year, from -$7.98M to $148.41M.
What is the long-term trend for Palvella Therapeutics's net change in cash?
Over 3 years (2022 to 2025), Palvella Therapeutics's net change in cash has grown at a -31.3% compound annual growth rate (CAGR), from -$79.13M to -$25.62M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Palvella Therapeutics's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude